Advances in treatment of mesothelioma

References

• Linton A, Pavlakis N, O’Connell R, et al. Factors associated with survival in a large series of patient with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111:1860–1869.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutation predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–1025.
   PubMed Web of Science ®Google Scholar
• Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413–1419.
   PubMed Web of Science ®Google Scholar
• Steyner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34:205–216.
   PubMed Web of Science ®Google Scholar
• Soeberg MJ, Takahashi K, Movahed M, et al. Global patterns in the incidence of malignant mesothelioma. 1988-2002, using data published by the International Agency for Research on Cancer (IARC). J Thorac Oncol. 2013;8:P2,14–007.
   Google Scholar
• Craighead JE. Epidemiology of mesothelioma and histological background. Rec Res Cancer Res. 2011;189:13–25.
   PubMedGoogle Scholar
• Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227:44–58.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Musk AW, Lake RA, et al. Malignant mesothelioma. Lancet. 2005;366:397–408.
   PubMed Web of Science ®Google Scholar
• Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNA in malignant mesothelioma – a miRNA microarray analysis. Gen Chrom Cancer. 2009;48:615–623.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Astouul P, Baas P, et al. Guidelines of the European respiratory society and the European society of thoracic surgeon for management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–495.
   PubMed Web of Science ®Google Scholar
• Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847–853.
   PubMed Web of Science ®Google Scholar
• Grossi F, Pennucci MC, Tixi L, et al. Management of malignant pleural effusions. Drugs. 1998;55(1):47–58.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Zarogoulidis P, Darwiche K. Malignant pleural effusion and algorithm management. J Thorac Dis. 2013;5(Suppl 4):S413–S419.
   Google Scholar
• Fasola G, Belvedere O, Aita M, et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial–an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist. 2007;12(10):1215–1224.
   PubMed Web of Science ®Google Scholar
• Greiller L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375–390.
   PubMed Web of Science ®Google Scholar
• Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. New Engl J Med. 2012;367(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353(15):1564–1573.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541–1549.
   PubMed Web of Science ®Google Scholar
• Panou V, Vyberg M, Weinreich UM, et al. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 2015;41(6):486–495.
   PubMed Web of Science ®Google Scholar
• Napolitano A, Antoine DJ, Pellegrini L, et al. HMGB1 and its hyper-acetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res. 2016. [Epub ahead of print]
   PubMedGoogle Scholar
• Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23–32.
   PubMed Web of Science ®Google Scholar
• Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–1047.
   PubMed Web of Science ®Google Scholar
• Armato SG III, Labby ZE, Coolen J, et al. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 2013;82:190–196.
   PubMed Web of Science ®Google Scholar
• Lopci E, Zucali PA, Ceresoli GL, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015;42(5):667–675.
   PubMed Web of Science ®Google Scholar
• De Perrot M, Feld R, Cho BCJ, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–1418.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Flores RM, Jaklisch MT, et al. Resection margins extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: result in 183 patients. J Thoracic Cardiovascolar Surg. 1999;117:54–63.
   PubMed Web of Science ®Google Scholar
• Cao C, Tian D, Manganas C, et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1:428–437.
   PubMedGoogle Scholar
• Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patient with malignant pleural mesothelioma (MesoVats): an open-label, randomized controlled trial. Lancet. 2014;384:1118–1127.
   PubMed Web of Science ®Google Scholar
• Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304–1312.
   PubMed Web of Science ®Google Scholar
• Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008;85:257–264.
   PubMed Web of Science ®Google Scholar
• Papaspyros S. Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies. ISRN Surg. 2014;2014:817203.
   PubMedGoogle Scholar
• Friedberg JS. The state of art in the technical performance of lung-sparing operations for malignant pleural mesothelioma. Semin Thorac Cardiovascular Surg. 2013;25:125–143.
   PubMedGoogle Scholar
• Cao C, Tian D, Park J, et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–245.
   PubMed Web of Science ®Google Scholar
• Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–626.
   PubMed Web of Science ®Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. Lancet Oncol. 2011;12(8):763–772.
   PubMed Web of Science ®Google Scholar
• Bovolato P, Casadio C, Billè A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390–396.
   PubMed Web of Science ®Google Scholar
• Price A. What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist. 2011;16:359–365.
   PubMed Web of Science ®Google Scholar
• Macleod N, Price A, O’Rouke N, et al. Radiotherapy for treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2014;83:133–138.
   PubMed Web of Science ®Google Scholar
• Baas P, Fennell D, Kerr MK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement5):v31–v39.
   Google Scholar
• Davies HE, Musk AW, Lee YC. Prophylactic radiotherapy for pleural puncture site in mesothelioma: the controversy continues. Curr Opin Pulm Med. 2008;14:326–330.
   PubMed Web of Science ®Google Scholar
• NCT01604005. PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma. [cited 2015 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01604005?term=NCT01604005&rank=1
   Google Scholar
• Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomized, international, multicenter phase 2 trial. Lancet Oncol. 2015. doi:10.1016/S1470-2045(15)00208-9.
   PubMed Web of Science ®Google Scholar
• Ahamad A, Stevens CW, Smyte WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;55(3):768–775.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238–245.
   PubMed Web of Science ®Google Scholar
• Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326.
   PubMed Web of Science ®Google Scholar
• Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys. 2009;73:9–14.
   PubMed Web of Science ®Google Scholar
• Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008;9(2–3):171–179.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552–558.
   PubMed Web of Science ®Google Scholar
• Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567–571.
   PubMed Web of Science ®Google Scholar
• Yasumitsu A, Tabata C, Tabata R, et al. Clinical significance of serum vascular endothelia growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5:479–483.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazières J, Margery J, et al. Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol. 2015;33(suppl) :400S.
   Google Scholar
• Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol. 2008;3(7):756–763.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–5936.
   PubMed Web of Science ®Google Scholar
• Cortinovis DL, Hollander LH, Floriani IC, et al. Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM). J Clin Oncol. 2015;33(suppl) :415S.
   Google Scholar
• Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicenter, randomized phase 3 study. Lancet Oncol. 2013;14:543–551.
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–2902.
   PubMed Web of Science ®Google Scholar
• van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2006;1:25–30.
   PubMed Web of Science ®Google Scholar
• NCT01085630. Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy. [cited 2015 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01085630?term=NCT+01085630&rank=1
   Google Scholar
• NCT 01870609. Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND). [cited 2015 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01870609?term=NCT+01870609&rank=1
   Google Scholar
• NCT01358084. Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (NGR019). [cited 2015 Nov 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01358084?term=NCT01358084&rank=1
   Google Scholar
• Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16(6):923–927.
   PubMed Web of Science ®Google Scholar
• Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26(10):1698–1704.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Wozniak AJ, Belani CP, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1(6):506–512.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, De Vincenzo F, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73–77.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63(1):94–97.
   PubMed Web of Science ®Google Scholar
• Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicenter randomized trial. Lancet. 2008;371(9625):1685–1694.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Millard F, Herndon JE 2nd, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001;31(2–3):311–317.
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112(7):1555–1561.
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84(3):271–274.
   PubMed Web of Science ®Google Scholar
• Zucali PA, Perrino M, Lorenzi E, et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer. 2014;84(3):265–270.
   PubMed Web of Science ®Google Scholar
• Gaafar RM, Favaretto AG, Gregorc V, et al. Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). J Clin Oncol. 2015;33(suppl) :400S.
   Google Scholar
• Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomized, placebo-controlled trial. Lancet Oncol. 2015;16(4):447–456.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Brown C, Millward MJ, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer. 2013;81(3):422–427.
   PubMed Web of Science ®Google Scholar
• Ou SH, Moon J, Garland LL, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015;10(2):387–391.
   PubMed Web of Science ®Google Scholar
• Villano JL, Husain AN, Stadler WM, et al. A phase II trial of imatinib mesylate in patients with malignant mesothelioma. J Clin Oncol. 2004;22(14S) :14S.
   Google Scholar
• Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer. 2005;50(1):83–86.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Pang H, Kratzke RA, et al. Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report. J Thorac Oncol. 2012;7(4):755–759.
   PubMed Web of Science ®Google Scholar
• Papa S, Popat S, Shah R, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8(6):783–787.
   PubMed Web of Science ®Google Scholar
• Dubey S, Jänne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010;5(10):1655–1661.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1449–1456.
   PubMed Web of Science ®Google Scholar
• Laurie SA, Gupta A, Chu Q, et al. The NCIC Clinical Trials Group. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol. 2011;6(11):1950–1954.
   PubMed Web of Science ®Google Scholar
• Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011;6(11):1938–1945.
   PubMed Web of Science ®Google Scholar
• Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012;78(1):76–80.
   PubMed Web of Science ®Google Scholar
• Govindan R, Kratzke RA, Herndon JE, et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11(6):2300–2304.
   PubMed Web of Science ®Google Scholar
• Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808–814.
   PubMed Web of Science ®Google Scholar
• Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25(17):2406–2413.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advance malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–1111.
   PubMed Web of Science ®Google Scholar
• Currie AJ, Prosser A, McDonnel A, et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death ligand I pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol. 2009;183:7898–7908.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Roden A, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology ad poor prognosis. J Thorac Oncol. 2014;9:1036–1040.
   PubMed Web of Science ®Google Scholar
• NCT01843374. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma. [cited 2015 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01843374?term=NCT01843374&rank=1
   Google Scholar
• Alley EW, Molife LR, Santoro A, et al. Abstract CT103: clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028. Cancer Res. 2015;75:CT103.
   Web of Science ®Google Scholar
• NCT02399371. Pembrolizumab in Treating Patients With Malignant Mesothelioma. [cited 2015 Nov 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02399371?term=NCT02399371&rank=1
   Google Scholar
• Truini A, Coco S, Alama A, et al. Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci. 2014;71(15):2865–2878.
   PubMed Web of Science ®Google Scholar
• Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015;10(3):492–499.
   PubMed Web of Science ®Google Scholar